1. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2026 update. Fontana (WI): GINA; 2026. Available from: https://ginasthma.org/wp-content/uploads/2026/05/GINA-2026-Strategy-Report-WMS.pdf

2. Ministry of Health and Population, Egypt, in collaboration with the Egyptian Society of Chest Diseases and Tuberculosis. Egyptian MoH asthma management protocol for adolescents and adults (Egyptian asthma guidelines for adolescents and adults). Cairo: Ministry of Health and Population; 2023.

3. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. Eur Respir J 2022; 60: 2101585. doi:10.1183/13993003.01585-2021

4. National Institute for Health and Care Excellence, British Thoracic Society, Scottish Intercollegiate Guidelines Network. Asthma: diagnosis, monitoring and chronic asthma management. BTS/NICE/SIGN joint guideline (NICE NG245; SIGN 245). London: NICE; November 2024. Available from: https://www.nice.org.uk/guidance/ng245

5. Halvorsen T, Walsted ES, Bucca C, et al. Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement. Eur Respir J 2017; 50: 1602221. doi:10.1183/13993003.02221-2016

6. Mortimer K, Masekela R, Ozoh O, et al. The reality of managing asthma in sub-Saharan Africa – priorities and strategies for improving care. J Pan Afr Thorac Soc 2022; 3: 105-120.

7. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019; 200: e70-e88. doi:10.1164/rccm.201908-1590ST

8. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022; 60: 2101499. doi:10.1183/13993003.01499-2021

9. Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49: 1601526. doi:10.1183/13993003.01526-2016

10. Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J 2018; 52: 1801033. doi:10.1183/13993003.01033-2018

11. Fahy JV. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol 2015; 15: 57-65. doi:10.1038/nri3786

12. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med 2015; 3: 290-300. doi:10.1016/S2213-2600(15)00050-8

13. Hartl S, Breyer MK, Burghuber OC, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J 2020; 55: 1901874. doi:10.1183/13993003.01874-2019

14. Amaral R, Jacinto T, Malinovschi A, et al. The influence of individual characteristics and non-respiratory diseases on blood eosinophil count. Clin Transl Allergy 2021; 11: e12036. doi:10.1002/clt2.12036

15. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. JAMA 2017; 317: 269-279. doi:10.1001/jama.2016.19627

16. Barnes PJ, Szefler SJ, Reddel HK, et al. Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. J Allergy Clin Immunol 2019; 144: 1180-1186. doi:10.1016/j.jaci.2019.06.040

17. O'Byrne PM, Reddel HK, Eriksson G, et al. Measuring asthma control: a comparison of three classification systems. Eur Respir J 2010; 36: 269-276. doi:10.1183/09031936.00124009

18. Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009; 18: 41-49. doi:10.4104/pcrj.2009.00010

19. Yawn BP, Wollan PC, Rank MA, et al. Use of Asthma APGAR Tools in Primary Care Practices: A Cluster-Randomized Controlled Trial. Ann Fam Med 2018; 16: 100-110. doi:10.1370/afm.2179

20. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59-65. doi:10.1016/j.jaci.2003.09.008

21. Jones PW, Tomaszewski EL, Belton L, et al. Validity of the Chronic Airways Assessment Test (CAAT) in asthma, asthma+COPD and COPD in NOVELTY. ERJ Open Res 2025; 11: 01359-2024. doi:10.1183/23120541.01359-2024

22. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020; 55: 1901872. doi:10.1183/13993003.01872-2019

23. Zheng XY, Ding H, Jiang LN, et al. Association between Air Pollutants and Asthma Emergency Room Visits and Hospital Admissions in Time Series Studies: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0138146. doi:10.1371/journal.pone.0138146

24. Redmond C, Akinoso-Imran AQ, Heaney LG, et al. Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: A systematic review and meta-analysis. J Allergy Clin Immunol 2022; 149: 1617-1627. doi:10.1016/j.jaci.2021.10.007

25. Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med 2025; 13: 505-516. doi:10.1016/S2213-2600(25)00037-2

26. Oosterholt S, Pavord ID, Brusselle G, et al. Modelling ASthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: A time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol 2023; 89: 3273-3290. doi:10.1111/bcp.15801

27. den Dekker HT, Sonnenschein-van der Voort AMM, de Jongste JC, et al. Early growth characteristics and the risk of reduced lung function and asthma: A meta-analysis of 25,000 children. J Allergy Clin Immunol 2016; 137: 1026-1035. doi:10.1016/j.jaci.2015.08.050

28. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev 2017; (4): CD012226. doi:10.1002/14651858.CD012226.pub2

29. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930-938. doi:10.1016/j.rmed.2011.01.005

30. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res 2018; 19: 10. doi:10.1186/s12931-017-0710-y

31. Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med 2017; 195: 302-313. doi:10.1164/rccm.201602-0419OC

32. Osborne ML, Pedula KL, O’Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007; 132: 1151-1161. doi:10.1378/chest.05-3084

33. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126: 1875-1882. doi:10.1378/chest.126.6.1875

34. Reddel HK, Busse WW, Pedersen S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 2017; 389: 157-166. doi:10.1016/S0140-6736(16)31399-X

35. Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev 2021; (5): CD013518. doi:10.1002/14651858.CD013518.pub2

36. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373. doi:10.1183/09031936.00202013

37. Heaney LG, Busby J, Bradding P, et al. Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. Am J Respir Crit Care Med 2019; 199: 454-464. doi:10.1164/rccm.201806-1182OC

38. Hale EM, Greene G, Mulvey C, et al. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med 2023; 11: 591-601. doi:10.1016/S2213-2600(22)00534-3

39. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA 2018; 319: 1485-1496. doi:10.1001/jama.2018.2769

40. Bao W, Zhang X, Yin J, et al. Small-Airway Function Variables in Spirometry, Fractional Exhaled Nitric Oxide, and Circulating Eosinophils Predicted Airway Hyperresponsiveness in Patients with Mild Asthma. J Asthma Allergy 2021; 14: 415-426. doi:10.2147/JAA.S295345

41. McNicholl DM, Stevenson M, McGarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186: 1102-1108. doi:10.1164/rccm.201204-0587OC

42. Buhl R, Bel E, Bourdin A, et al. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract 2022; 10: 422-432. doi:10.1016/j.jaip.2021.10.059

43. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146: 1217-1270. doi:10.1016/j.jaci.2020.10.003

44. Wang Z, Pianosi P, Keogh K, et al. The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management. Comparative Effectiveness Review No. 197. Rockville (MD): Agency for Healthcare Research and Quality; 2017. doi:10.23970/AHRQEPCCER197

45. Petsky HL, Li AM, Au CT, et al. Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: A dual centre randomized controlled trial. Pediatr Pulmonol 2015; 50: 535-543. doi:10.1002/ppul.23064

46. Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ, et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax 2015; 70: 543-550. doi:10.1136/thoraxjnl-2014-206161

47. Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol 2014; 49: 624-631. doi:10.1002/ppul.22873

48. Leas BF, D’Anci KE, Apter AJ, et al. Effectiveness of indoor allergen reduction in management of asthma. Comparative Effectiveness Review No. 201. Rockville (MD): Agency for Healthcare Research and Quality; 2018. doi:10.23970/AHRQEPCCER201

49. Matsui EC, Perzanowski M, Peng RD, et al. Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma: A Randomized Clinical Trial. JAMA 2017; 317: 1027-1036. doi:10.1001/jama.2016.21048

50. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008; (2): CD001187. doi:10.1002/14651858.CD001187.pub3

51. Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566-577. doi:10.1164/rccm.200906-0907OC

52. Stapleton M, Howard-Thompson A, George C, et al. Smoking and asthma. J Am Board Fam Med 2011; 24: 313-322. doi:10.3122/jabfm.2011.03.100180

53. McConnell R, Barrington-Trimis JL, Wang K, et al. Electronic Cigarette Use and Respiratory Symptoms in Adolescents. Am J Respir Crit Care Med 2017; 195: 1043-1049. doi:10.1164/rccm.201604-0804OC

54. Okoniewski W, Lu KD, Forno E. Weight Loss for Children and Adults with Obesity and Asthma. A Systematic Review of Randomized Controlled Trials. Ann Am Thorac Soc 2019; 16: 613-625. doi:10.1513/AnnalsATS.201810-651SR

55. Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012; (7): CD009339. doi:10.1002/14651858.CD009339.pub2

56. Moreira A, Bonini M, Garcia-Larsen V, et al. Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). Allergy 2013; 68: 425-439. doi:10.1111/all.12106

57. Carson KV, Chandratilleke MG, Picot J, et al. Physical training for asthma. Cochrane Database Syst Rev 2013; (9): CD001116. doi:10.1002/14651858.CD001116.pub4

58. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187: 1016-1027. doi:10.1164/rccm.201303-0437ST

59. Dogaru CM, Nyffenegger D, Pescatore AM, et al. Breastfeeding and childhood asthma: systematic review and meta-analysis. Am J Epidemiol 2014; 179: 1153-1167. doi:10.1093/aje/kwu072

60. Lodge CJ, Tan DJ, Lau MX, et al. Breastfeeding and asthma and allergies: a systematic review and meta-analysis. Acta Paediatr 2015; 104: 38-53. doi:10.1111/apa.13132

61. Mastronarde JG, Anthonisen NR, Castro M, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360: 1487-1499. doi:10.1056/NEJMoa0806290

62. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117: 27-56. doi:10.14309/ajg.0000000000001538

63. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med 2018; 378: 1865-1876. doi:10.1056/NEJMoa1715274

64. Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. N Engl J Med 2019; 380: 2020-2030. doi:10.1056/NEJMoa1901963

65. Papi A, Chipps BE, Beasley R, et al. Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med 2022; 386: 2071-2083. doi:10.1056/NEJMoa2203163

66. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071-1076. doi:10.1016/S0140-6736(03)12891-7

67. Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; (5): CD005535. doi:10.1002/14651858.CD005535.pub2

68. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207. doi:10.1056/NEJMoa1208606

69. Chauhan BF, Jeyaraman MM, Singh Mann A, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev 2017; (3): CD010347. doi:10.1002/14651858.CD010347.pub2

70. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018; 11: 193-204. doi:10.2147/JAA.S176026

71. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476. doi:10.1016/j.jaci.2010.06.047

72. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2020; (9): CD011293. doi:10.1002/14651858.CD011293.pub3

73. Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA 2016; 315: 1715-1725. doi:10.1001/jama.2016.3964

74. Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res 2012; 13: 59. doi:10.1186/1465-9921-13-59

75. McKeever T, Mortimer K, Wilson A, et al. Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations. N Engl J Med 2018; 378: 902-910. doi:10.1056/NEJMoa1714257

76. Hawkins G, McMahon AD, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326: 1115. doi:10.1136/bmj.326.7399.1115

77. Rank MA, Hagan JB, Park MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131: 724-729. doi:10.1016/j.jaci.2012.11.038

78. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; (8): CD001186. doi:10.1002/14651858.CD001186.pub2

79. Tay TR, Hew M. Comorbid "treatable traits" in difficult asthma: Current evidence and clinical evaluation. Allergy 2018; 73: 1369-1382. doi:10.1111/all.13370

80. Burks AW, Tang M, Sicherer S, et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129: 906-920. doi:10.1016/j.jaci.2012.02.001

81. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy 2013; 68: 569-579. doi:10.1111/all.12124

82. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58 Suppl S29: 1-464. doi:10.4193/Rhin20.600

83. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-1650. doi:10.1016/S0140-6736(19)31881-1

84. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146: 595-605. doi:10.1016/j.jaci.2020.05.032

85. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. GINA pocket guide for health professionals, 2025. Fontana (WI): GINA; 2025. Available from: https://ginasthma.org/severeasthma/

86. Serrano-Pariente J, Plaza V, Soriano JB, et al. Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea. Allergy 2017; 72: 802-812. doi:10.1111/all.13070

87. Teodorescu M, Barnet JH, Hagen EW, et al. Association between asthma and risk of developing obstructive sleep apnea. JAMA 2015; 313: 156-164. doi:10.1001/jama.2014.17822

88. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007; 175: 661-666. doi:10.1164/rccm.200611-1717OC

89. Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008; 179: 1121-1131. doi:10.1503/cmaj.081332

90. Freitas PD, Ferreira PG, Silva AG, et al. The Role of Exercise in a Weight-Loss Program on Clinical Control in Obese Adults with Asthma. A Randomized Controlled Trial. Am J Respir Crit Care Med 2017; 195: 32-42. doi:10.1164/rccm.201603-0446OC

91. Scott HA, Gibson PG, Garg ML, et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy 2013; 43: 36-49. doi:10.1111/cea.12004

92. Thomas M, Bruton A, Moffat M, et al. Asthma and psychological dysfunction. Prim Care Respir J 2011; 20: 250-256. doi:10.4104/pcrj.2011.00058

93. Foster JM, McDonald VM, Guo M, et al. "I have lost in every facet of my life": the hidden burden of severe asthma. Eur Respir J 2017; 50: 1700765. doi:10.1183/13993003.00765-2017

94. Kew KM, Nashed M, Dulay V, et al. Cognitive behavioural therapy (CBT) for adults and adolescents with asthma. Cochrane Database Syst Rev 2016; (9): CD011818. doi:10.1002/14651858.CD011818.pub2

95. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16: 432-436. doi:10.1034/j.1399-3003.2000.016003432.x

96. Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol 2015; 135: 676-681.e1. doi:10.1016/j.jaci.2014.08.020

97. Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, et al. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 2004; 10: 51-56. doi:10.1097/00063198-200401000-00009

98. Morales DR, Lipworth BJ, Guthrie B, et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014; 134: 40-45. doi:10.1016/j.jaci.2013.10.057

99. Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 9-14. doi:10.1164/ajrccm.165.1.2010080

100. Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014; 69: 130-136. doi:10.1136/thoraxjnl-2013-203557

101. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-873. doi:10.1111/cea.12141

102. Agarwal R, Sehgal IS, Muthu V, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J 2024; 63: 2400061. doi:10.1183/13993003.00061-2024

103. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax 2006; 61: 169-176. doi:10.1136/thx.2005.049718

104. Murphy VE, Namazy JA, Powell H, et al. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG 2011; 118: 1314-1323. doi:10.1111/j.1471-0528.2011.03055.x

105. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J 2020; 55: 1901208. doi:10.1183/13993003.01208-2019

106. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med 2011; 32: 93-110. doi:10.1016/j.ccm.2010.10.001

107. Murphy VE, Powell H, Wark PAB, et al. A prospective study of respiratory viral infection in pregnant women with and without asthma. Chest 2013; 144: 420-427. doi:10.1378/chest.12-1956

108. Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174: 127-133. doi:10.1164/rccm.200510-1589OC

109. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175: 783-790. doi:10.1164/rccm.200511-1746OC

110. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report. Available from: https://goldcopd.org

111. Hanania NA, Celli BR, Donohue JF, et al. Bronchodilator reversibility in COPD. Chest 2011; 140: 1055-1063. doi:10.1378/chest.10-2974

112. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; (3): CD010115. doi:10.1002/14651858.CD010115.pub2

113. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036. doi:10.1136/thoraxjnl-2012-202872

114. van Huisstede A, Castro Cabezas M, van de Geijn GJ, et al. Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respir Med 2013; 107: 1356-1364. doi:10.1016/j.rmed.2013.05.007

115. Levy ML, Nicholson PJ. Occupational asthma case finding: a role for primary care. Br J Gen Pract 2004; 54: 731-733.

116. Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. Eur Respir J 2012; 39: 529-545. doi:10.1183/09031936.00096111

117. Henneberger PK, Patel JR, de Groene GJ, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2019; (10): CD006308. doi:10.1002/14651858.CD006308.pub4

118. Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134: 1S-41S. doi:10.1378/chest.08-0201

119. Sánchez-Ramos JL, Pereira-Vega AR, Alvarado-Gómez F, et al. Risk factors for premenstrual asthma: a systematic review and meta-analysis. Expert Rev Respir Med 2017; 11: 57-72. doi:10.1080/17476348.2017.1270762

120. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006; 144: 581-595. doi:10.7326/0003-4819-144-8-200604180-00009

121. Woods BD, Sladen RN. Perioperative considerations for the patient with asthma and bronchospasm. Br J Anaesth 2009; 103 Suppl 1: i57-i65. doi:10.1093/bja/aep271

122. Coker RK, Armstrong A, Church AC, et al. BTS Clinical Statement on air travel for passengers with respiratory disease. Thorax 2022; 77: 329-350. doi:10.1136/thoraxjnl-2021-218110

123. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910-917. doi:10.1136/thx.2010.153643

124. Egyptian Scientific Society of Bronchology (ESSB). Stepwise approach of asthma and COPD management in the emergency room and intensive care unit. Egypt: ESSB; 2019.

125. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604-610. doi:10.1164/ajrccm.149.3.8118625

126. Perrin K, Wijesinghe M, Healy B, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax 2011; 66: 937-941. doi:10.1136/thx.2010.155259

127. Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; (1): CD002178. doi:10.1002/14651858.CD002178

128. Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev 2014; (5): CD010909. doi:10.1002/14651858.CD010909.pub2

129. Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma. Cochrane Database Syst Rev 2012; (12): CD002742. doi:10.1002/14651858.CD002742.pub2

130. Normansell R, Sayer B, Waterson S, et al. Antibiotics for exacerbations of asthma. Cochrane Database Syst Rev 2018; (6): CD002741. doi:10.1002/14651858.CD002741.pub2

131. Mazenq J, Dubus JC, Gaudart J, et al. City housing atmospheric pollutant impact on emergency visit for asthma: A classification and regression tree approach. Respir Med 2017; 132: 1-8. doi:10.1016/j.rmed.2017.09.004

132. Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006; 61: 376-382. doi:10.1136/thx.2005.042523

133. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 2002; 288: 963-972. doi:10.1001/jama.288.8.963

134. Lodge CJ, Lowe AJ, Gurrin LC, et al. Pets at birth do not increase allergic disease in at-risk children. Clin Exp Allergy 2012; 42: 1377-1385. doi:10.1111/j.1365-2222.2012.04032.x

135. Burke H, Leonardi-Bee J, Hashim A, et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. Pediatrics 2012; 129: 735-744. doi:10.1542/peds.2011-2196

136. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Cochrane Database Syst Rev 2012; (9): CD000133. doi:10.1002/14651858.CD000133.pub3